Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Roma La Sapienza | OTHER |
| Catholic University of the Sacred Heart | OTHER |
| University of Turin, Italy | OTHER |
| University of Catania |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of this multicentric 5-year follow-up study is to evaluate for the first time the long-term efficacy and safety (in terms of smoking-related serious diseases requiring hospitalization) of e-cigarette smoking, comparing its health effects with those of traditional cigarette smoking and mixed electronic and traditional cigarette smoking.
The study will also permit to evaluate, over a 5-year follow-up, the self-reported quality of life, and the reported adverse events according to current and past smoking habit.
Finally, the study will also explore the long-term adherence to e-cigarette smoking and its efficacy of e-cigarettes in reducing and/or quitting traditional cigarette smoking.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| E-cigarettes only | Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes | ||
| Traditional cigarettes only | Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers. | ||
| Mixed group | Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Traditional smoking cessation rate | Percentage of subjects that were current (in TC and Mixed groups) or former (in EC group) smokers reporting sustained smoking abstinence from traditional cigarette smoking at 60 months. Smoking abstinence is defined as complete abstinence from tobacco smoking (not even a puff) for the 30 days period prior to the visit. This outcome will be self-reported and checked using CO analyzer after breath. | 5 years |
| Change from baseline in the number of traditional cigarette smoked | Change in the average self-reported number of traditional cigarette smoked per day. | 6, 12, 24, 36 and 60 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of subjects with smoking-related hospitalizations | Percentage of subjects who had a hospital admission for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Repeated admissions of the same subject will be counted once. | 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Adult residents in the Abruzzo and Lazio Region of Italy that are smokers of traditional or electronic cigarettes
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lamberto Manzoli, MD, MPH | Department of Medicine and Aging Sciences, University of Chieti, Italy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Medicine and Aging Sciences, University of Chieti | Chieti | CH | 66100 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24063569 | Background | Manzoli L, La Vecchia C, Flacco ME, Capasso L, Simonetti V, Boccia S, Di Baldassarre A, Villari P, Mezzetti A, Cicolini G. Multicentric cohort study on the long-term efficacy and safety of electronic cigarettes: study design and methodology. BMC Public Health. 2013 Sep 24;13:883. doi: 10.1186/1471-2458-13-883. | |
| 26061661 | Result |
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Apr 22, 2020 | |
| Reset | May 5, 2020 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Apr 22, 2020 | May 5, 2020 |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D008175 | Lung Neoplasms |
| D001749 | Urinary Bladder Neoplasms |
| D013274 | Stomach Neoplasms |
| D000073865 | Cigarette Smoking |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| OTHER |
| Mario Negri Institute for Pharmacological Research | OTHER |
Not provided
Not provided
Not provided
| Number of smoking-related hospitalizations | Mean number of hospital admissions for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Each admissions of the same subject will be counted. | 5 years |
| Number of hospitalizations for cardiovascular diseases | Mean number of hospital admissions for cardiovascular diseases. Each admissions of the same subject will be counted. | 5 years |
| Number of hospitalizations for smoking-related cancers | Mean number of hospital admissions for cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Each admissions of the same subject will be counted. | 5 years |
| Change from baseline in self-reported quality of life | Change in the average quality of life according to EuroQol EQ-D3. | 6, 12, 24 and 36 months |
| Time to hospitalization for cardiovascular diseases, COPD and smoking-related cancer. | Time to hospital admission for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Repeated admissions of the same subject will be counted once and the subject will be censored at the date of the first admission. | 5 year |
| Number of Participants with Adverse Events as a Measure of Safety and tolerability | Self-reported side effects as measured by VAS and a structured report form. | 5 years |
| Adherence to e-cigarette smoking | Number of months of continued e-cigarette smoking in groups EC and Mixed. | 5 years |
| Time to hospitalization for cardiovascular diseases, COPD and smoking-related cancer. | The primary outcome measure is time to hospital admission for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Repeated admissions of the same subject will be counted once and the subject will be censored at the date of the first admission. | 3 years |
| Time to hospitalization for cardiovascular diseases, COPD and smoking-related cancer. | The primary outcome measure is time to hospital admission for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Repeated admissions of the same subject will be counted once and the subject will be censored at the date of the first admission. | 2 years |
| Rate of subjects with smoking-related hospitalizations | Percentage of subjects who had a hospital admission for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Repeated admissions of the same subject will be counted once. | 3 years |
| Rate of subjects with smoking-related hospitalizations | Percentage of subjects who had a hospital admission for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Repeated admissions of the same subject will be counted once. | 2 years |
| Number of smoking-related hospitalizations | Mean number of hospital admissions for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Each admissions of the same subject will be counted. | 2 years |
| Number of smoking-related hospitalizations | Mean number of hospital admissions for one of the followings: cardiovascular diseases, chronic obstructive pulmonary diseases, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia. Each admissions of the same subject will be counted. | 1 year |
| Smoking abstinence | Percentage of subjects reporting sustained smoking abstinence from traditional cigarette smoking. Smoking abstinence is defined as complete abstinence from tobacco smoking (not even a puff) for the 30 days period prior to the visit. | 3 years |
| Smoking abstinence | Percentage of subjects reporting sustained smoking abstinence from traditional cigarette smoking. Smoking abstinence is defined as complete abstinence from tobacco smoking (not even a puff) for the 30 days period prior to the visit. | 2 years |
| Smoking abstinence | Percentage of subjects reporting sustained smoking abstinence from traditional cigarette smoking. Smoking abstinence is defined as complete abstinence from tobacco smoking (not even a puff) for the 30 days period prior to the visit. | 1 year |
| Smoking abstinence | Percentage of subjects reporting sustained smoking abstinence from traditional cigarette smoking. Smoking abstinence is defined as complete abstinence from tobacco smoking (not even a puff) for the 30 days period prior to the visit. | 6 months |
| Number of Participants with Adverse Events as a Measure of Safety and tolerability | Self-reported side effects as measured by VAS and a structured report form. | 3 years |
| Number of Participants with Adverse Events as a Measure of Safety and tolerability | Self-reported side effects as measured by VAS and a structured report form. | 2 years |
| Number of Participants with Adverse Events as a Measure of Safety and tolerability | Self-reported side effects as measured by VAS and a structured report form. | 1 year |
| Number of Participants with Adverse Events as a Measure of Safety and tolerability | Self-reported side effects as measured by VAS and a structured report form. | 6 months |
| Adherence to e-cigarette smoking | Number of months of continued e-cigarette smoking in groups EC and Mixed. | 3 years |
| Adherence to e-cigarette smoking | Number of months of continued e-cigarette smoking in groups EC and Mixed. | 2 years |
| Adherence to e-cigarette smoking | Number of months of continued e-cigarette smoking in groups EC and Mixed. | 1 year |
| Adherence to e-cigarette smoking | Number of months of continued e-cigarette smoking in groups EC and Mixed. | 6 months |
| Traditional and electronic smoking (overall smoking) cessation | Percentage of subjects in all groups reporting sustained smoking abstinence from both traditional and electronic cigarette smoking at 12 months. Smoking abstinence is defined as complete abstinence from tobacco or electronic smoking (not even a puff) for the 30 days period prior to the visit. | 1 year |
| Manzoli L, Flacco ME, Fiore M, La Vecchia C, Marzuillo C, Gualano MR, Liguori G, Cicolini G, Capasso L, D'Amario C, Boccia S, Siliquini R, Ricciardi W, Villari P. Electronic Cigarettes Efficacy and Safety at 12 Months: Cohort Study. PLoS One. 2015 Jun 10;10(6):e0129443. doi: 10.1371/journal.pone.0129443. eCollection 2015. |
| Result | Manzoli L, Flacco ME, Ferrante M, La Vecchia C, Siliquini R, Ricciardi W, Marzuillo C, Villari P, Fiore M. A cohort study of electronic cigarette use: Effectiveness and safety at 24 months. Tobacco Control 2016 Jun 7 (epub ahead of print). (doi: 10.1136/tobaccocontrol-2015-052822) Direct link: http://tobaccocontrol.bmj.com/content/early/2016/06/06/tobaccocontrol-2015-052822.full |
| 27272748 | Derived | Manzoli L, Flacco ME, Ferrante M, La Vecchia C, Siliquini R, Ricciardi W, Marzuillo C, Villari P, Fiore M; ISLESE Working Group. Cohort study of electronic cigarette use: effectiveness and safety at 24 months. Tob Control. 2017 May;26(3):284-292. doi: 10.1136/tobaccocontrol-2015-052822. Epub 2016 Jun 6. |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |
| D000073869 | Tobacco Smoking |
| D012907 | Smoking |
| D001519 | Behavior |
| D064424 | Tobacco Use |